Pictet Asset Management
VIR icon

Pictet Asset Management’s Vir Biotechnology VIR Stock Holding History

Pictet Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3M Buy
1,480,828
+1,467,340
+10,879% +$11.7M 0.01% 585
2025
Q4 		$81.3K Hold
13,488
– – ﹤0.01% 2043
2025
Q3 		$77K Hold
13,488
– – ﹤0.01% 2003
2025
Q2 		$68K Hold
13,488
– – ﹤0.01% 1975
2025
Q1 		$87.4K Buy
+13,488
New +$120K ﹤0.01% 1947

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Pictet Asset Management's VIR Position: Q1 2026 in Review

Pictet Asset Management increased its Vir Biotechnology (VIR) stake by 10,879% in Q1 2026, buying an estimated $11.7M and bringing the position to 1,480,828 shares worth $13.3M. The position accounts for 0.01% of the portfolio, ranked #585.

Pictet Asset Management first reported a position in VIR in Q1 2025 and has held it in 5 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Pictet Asset Management held 1,480,828 shares of Vir Biotechnology worth $13.3M as of Q1 2026.
  • Pictet Asset Management bought 1,467,340 Vir Biotechnology shares in Q1 2026, an estimated $11.7M.
  • Vir Biotechnology made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #585 holding.
  • Pictet Asset Management first reported a position in Vir Biotechnology in Q1 2025 and has held it in 5 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.